Lixte Biotechnology (LIXT) Competitors $1.32 +0.01 (+0.38%) As of 05/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. SNYR, COCP, CING, LPCN, UBX, UPXI, MBRX, NRSN, INAB, and FLGCShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Synergy CHC Corp. (Uplisting) (SNYR), Cocrystal Pharma (COCP), Cingulate (CING), Lipocine (LPCN), Unity Biotechnology (UBX), Upexi (UPXI), Moleculin Biotech (MBRX), NeuroSense Therapeutics (NRSN), IN8bio (INAB), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Synergy CHC Corp. (Uplisting) Cocrystal Pharma Cingulate Lipocine Unity Biotechnology Upexi Moleculin Biotech NeuroSense Therapeutics IN8bio Flora Growth Lixte Biotechnology (NASDAQ:LIXT) and Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Do analysts prefer LIXT or SNYR? Synergy CHC Corp. (Uplisting) has a consensus price target of $10.00, indicating a potential upside of 376.19%. Given Synergy CHC Corp. (Uplisting)'s stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC Corp. (Uplisting) is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is LIXT or SNYR more profitable? Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Lixte BiotechnologyN/A -5,562.77% -130.48% Synergy CHC Corp. (Uplisting) N/A N/A N/A Does the media favor LIXT or SNYR? In the previous week, Synergy CHC Corp. (Uplisting) had 44 more articles in the media than Lixte Biotechnology. MarketBeat recorded 45 mentions for Synergy CHC Corp. (Uplisting) and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.00 equaled Synergy CHC Corp. (Uplisting)'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synergy CHC Corp. (Uplisting) 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has preferable valuation and earnings, LIXT or SNYR? Synergy CHC Corp. (Uplisting) has higher revenue and earnings than Lixte Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLixte BiotechnologyN/AN/A-$5.09M-$1.45-0.91Synergy CHC Corp. (Uplisting)$34.83M0.53N/AN/AN/A Do institutionals & insiders have more ownership in LIXT or SNYR? 5.1% of Lixte Biotechnology shares are held by institutional investors. 14.8% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in LIXT or SNYR? Synergy CHC Corp. (Uplisting) received 2 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformLixte BiotechnologyN/AN/ASynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% SummarySynergy CHC Corp. (Uplisting) beats Lixte Biotechnology on 9 of the 11 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.53M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.768.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book5.986.466.804.50Net Income-$5.09M$143.98M$3.23B$248.18M7 Day Performance-8.68%2.03%1.53%0.23%1 Month Performance12.39%4.11%10.05%12.39%1 Year Performance-45.88%-2.87%16.75%7.07% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.3233 of 5 stars$1.32+0.4%N/A-47.2%$3.53MN/A-0.764SNYRSynergy CHC Corp. (Uplisting)2.5636 of 5 stars$1.83+3.4%$10.00+446.4%N/A$16.02M$34.83M0.0040Trending NewsEarnings ReportAnalyst RevisionGap UpCOCPCocrystal Pharma3.1462 of 5 stars$1.57+3.0%$7.00+347.3%-24.7%$15.92MN/A-0.8510Earnings ReportAnalyst RevisionCINGCingulate2.3098 of 5 stars$3.98-0.7%$30.67+670.5%+301.2%$15.69MN/A-0.4720News CoverageAnalyst ForecastAnalyst RevisionLPCNLipocine1.5258 of 5 stars$2.92-11.0%$10.00+242.5%-44.6%$15.62M$11.20M-3.8410Gap UpHigh Trading VolumeUBXUnity Biotechnology3.6596 of 5 stars$0.90-1.5%$5.33+492.6%-49.5%$15.49M$240,000.00-0.6960UPXIUpexi0.7667 of 5 stars$10.64+7.4%N/A+36.0%$15.17M$18.63M0.00130Earnings ReportHigh Trading VolumeMBRXMoleculin Biotech1.9585 of 5 stars$1.08+2.9%$6.00+455.6%-80.4%$15.12MN/A0.0020NRSNNeuroSense Therapeutics2.4447 of 5 stars$1.10+5.4%N/A+19.0%$15.03MN/A-1.7210INABIN8bio3.2045 of 5 stars$0.16+3.6%$6.00+3,581.0%-87.5%$14.80MN/A-0.2220FLGCFlora Growth2.4992 of 5 stars$0.75+10.5%$5.00+566.7%-47.5%$14.58M$59.51M-0.57280Gap Down Related Companies and Tools Related Companies SNYR Alternatives COCP Alternatives CING Alternatives LPCN Alternatives UBX Alternatives UPXI Alternatives MBRX Alternatives NRSN Alternatives INAB Alternatives FLGC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LIXT Stock Free LIXT Stock Alerts